BIT-MAP
LIVE

Serial Number

79290762

Owner

bitBiome, Inc.

Attorney

Stacey J. Watson, Esq.

Filing Date

Feb 6, 2020

Add to watchlist:

No watchlists yet
View on USPTO

BIT-MAP Trademark

Serial Number: 79290762 • Registration: 6337404

BIT-MAP is a trademark filed by bitBiome, Inc. on February 6, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

bitBiome, Inc. (5 trademarks)

1-22-3, Nishi-waseda, Shinjuku-ku

Entity Type: 03

Trademark Details

Filing Date

February 6, 2020

Registration Date

May 4, 2021

Published for Opposition

February 16, 2021

Goods & Services

Pharmaceutical preparations for the treatment of allergies, alzheimer disease, adrenocortical insufficiency, allotype pneumonia, alveobronchiolitis, angiocholitis, arthritis, asthmatoid bronchitis, asthma, attention deficit hyperactivity disorder, autism, auto-immune diseases and disorders, autoinflammatory disease, bacteremia, bacterial infection, bacterial pneumonia, bacterial septicemia, bacteroides fragilis, bacteroides thetaiotaomicron, bacteroides uniformis, bacteroides vulgatus, beta thalassemia and myelodysplastic syndromes, and biliary tract cancer, pneumonia, blood disease, blood disorders, bone growth disorders, bone and joint infections, breast cancer, bronchitis, bronchiectasis, cancer, cardiovascular diseases, central nervous system diseases and disorders, cervical cancer, cholecystitis, chronic congestive heart failure, clostridium perfringens, collagen diseases, colorectal cancer, community-acquired pneumonia, congestive heart failure, constipation, crohn's disease, cystitis, deep suppurative disease, dementia, depression, diabetes, dermatologic diseases, duodenal ulcer, dysentery, edematous states, endocarditis, endocrine diseases and disorders, endometrial cancer, endometriosis, endonephritis, enteritis, enterococcus faecalis, epididymitis, epilepsy, esophageal cancer, dysentery, febrile neutropenic infections, gastrointestinal diseases and disorders, gastric cancer, gastric ulcer, genetic diseases and disorders, gonorrhea, graft-versus-host disease, granulocytopenia, gynecological infections, head and neck cancer, heart disease, hematologic disorders, hepatic cirrhosis, hypertension, hyperlipidemi, hypercholesterolemia, hypognathadenitis, incontinence, inflammation and inflammatory diseases, inflammatory bowel disease, intra-abdominal infections, intrauterine infection, irritable bowel syndrome, kidney diseases and disorders, leukemia, liver disorders and diseases, lower respiratory tract infections, lung cancer, lymphoma, melanoma, meningitis, menopausal, metabolic diseases and disorders, multiple myeloma, multiple sclerosis, muscular dystrophy, musculoskeletal diseases and disorders, myeloproliferative diseases, myelofibrosis, nasosinusitis, neoplastic diseases, neurodegenerative diseases and disorders, neurological diseases and disorders, neuromuscular and non-gonococcal urethritis, nosocomial pneumonia, obesity, obsessive-compulsive disorder, oncological diseases and disorders, ophthalmic diseases, osteoarthritis, otitis media, ovarian cancer, pain, pancreatic cancer, parkinson's disease, peptostreptococcus micros, peritonitis and septicemia, pneumonia, polymicrobic infections, prevention of chest pain, prostate cancer, prostatitis, pseudomonas aeruginosa, pyelocystiti, pyelonephritis, reflux sophagitis, renal dysfunction, rheumatic disorders, respiratory diseases, respiratory tract infections, schizophrenia, scleroderma, seizures, septicemia, sexual disfunction, sickle cell disease, skin disorders and diseases, skin and skin structure infections, solid organ transplant rejection, spasms, staphylococcus aureus, streptococcus anginosus, streptococcus intermadius, streptococcus constellatus, stroke, superficial pyogenic infection, suppurative lung disease, syphilis, transmissible alimentary toxicosis, the prevention of organ rejection by renal transplant patients, tumors, ulcerative colitis, urethritis, urinary tract infections, urogenital tract infection, urothelial cancer, vaso-occulisive crisis, viral diseases and disorders, and zollinger-ellison syndrome; pharmaceutical biological preparations for medical purposes for the treatment of allergies, alzheimer disease, adrenocortical insufficiency, allotype pneumonia, alveobronchiolitis, angiocholitis, arthritis, asthmatoid bronchitis, asthma, attention deficit hyperactivity disorder, autism, auto-immune diseases and disorders, autoinflammatory disease, bacteremia, bacterial infection, bacterial pneumonia, bacterial septicemia, bacteroides fragilis, bacteroides thetaiotaomicron, bacteroides uniformis, bacteroides vulgatus, beta thalassemia and myelodysplastic syndromes, biliary tract cancer, pneumonia, blood disease, blood disorders, bone growth disorders, bone and joint infections, breast cancer, bronchitis, bronchiectasis, cancer, cardiovascular diseases, central nervous system diseases and disorders, cervical cancer, cholecystitis, chronic congestive heart failure, clostridium perfringens, collagen diseases, colorectal cancer, community-acquired pneumonia, congestive heart failure, constipation, crohn's disease, cystitis, deep suppurative disease, dementia, depression, diabetes, dermatologic diseases, duodenal ulcer, dysentery, edematous states, endocarditis, endocrine diseases and disorders, endometrial cancer, endometriosis, endonephritis, enteritis, enterococcus faecalis, epididymitis, epilepsy, esophageal cancer, dysentery, febrile neutropenic infections, gastrointestinal diseases and disorders, gastric cancer, gastric ulcer, genetic diseases and disorders, gonorrhea, graft-versus-host disease, granulocytopenia, gynecological infections, head and neck cancer, heart disease, hematologic disorders, hepatic cirrhosis, hypertension, hyperlipidemi, hypercholesterolemia, hypognathadenitis, incontinence, inflammation and inflammatory diseases, inflammatory bowel disease, intra-abdominal infections, intrauterine infection, irritable bowel syndrome, kidney diseases and disorders, leukemia, liver disorders and diseases, lower respiratory tract infections, lung cancer, lymphoma, melanoma, meningitis, menopausal, metabolic diseases and disorders, multiple myeloma, multiple sclerosis, muscular dystrophy, musculoskeletal diseases and disorders, myeloproliferative diseases, myelofibrosis, nasosinusitis, neoplastic diseases, neurodegenerative diseases and disorders, neurological diseases and disorders, neuromuscular and non-gonococcal urethritis, nosocomial pneumonia, obesity, obsessive-compulsive disorder, oncological diseases and disorders, ophthalmic diseases, osteoarthritis, otitis media, ovarian cancer, pain, pancreatic cancer, parkinson's disease, peptostreptococcus micros, peritonitis and septicemia, pneumonia, polymicrobic infections, prevention of chest pain, prostate cancer, prostatitis, pseudomonas aeruginosa, pyelocystiti, pyelonephritis, reflux sophagitis, renal dysfunction, rheumatic disorders, respiratory diseases, respiratory tract infections, schizophrenia, scleroderma, seizures, septicemia, sexual disfunction, sickle cell disease, skin disorders and diseases, skin and skin structure infections, solid organ transplant rejection, spasms, staphylococcus aureus, streptococcus anginosus, streptococcus intermadius, streptococcus constellatus, stroke, superficial pyogenic infection, suppurative lung disease, syphilis, transmissible alimentary toxicosis, the prevention of organ rejection by renal transplant patients, tumors, ulcerative colitis, urethritis, urinary tract infections, urogenital tract infection, urothelial cancer, vaso-occulisive crisis, viral diseases and disorders, and zollinger-ellison syndrome; pharmaceutical preparations for human use, namely, analgesics, antibiotics, anti-fungals, anti-infective preparations, anti-virals, anti-parasitics, and cytokine inhibitory drugs; human growth hormones, immunosuppressants, immunotherapies for the treatment of cancer, medicated dermatological preparations, pharmaceutical antibodies for disease testing, diagnosis, and treatment purposes, pharmaceutical preparations that modulate the immune system, pharmaceutical and biological preparations for immunotherapy, including T Cell therapy, sedatives, smoking cessation preparations, tranquillizers, vaccines for human use, and vitamins; preparations for destroying vermin, fungicides, herbicides

Medical screening; providing information relating to medical services; medical testing and physical examination for diagnostic or treatment purposes

Structural and functional analysis of genomes; research and development in the field of microorganisms and cells for the healthcare, scientific, biochemical, pharmaceutical, medical, agricultural, food, cosmetic, animal health, diagnostic, chemical, bioremediation, sanitation, oral care, and oil industries; pharmaceutical research and development; pharmaceutical product evaluation services; medical research; medical laboratory research in the field of genetics; scientific laboratory services in the field of gene expression; scientific research relating to genetics

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Jan 19, 2024 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Sep 5, 2021 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Aug 12, 2021 FICS
FINAL DISPOSITION PROCESSED
Aug 12, 2021 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Aug 4, 2021 FICR
REGISTERED-PRINCIPAL REGISTER
May 4, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 16, 2021 NPUB
PUBLISHED FOR OPPOSITION
Feb 16, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 27, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 8, 2021 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 8, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 8, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 8, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 8, 2021 CNEA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jan 7, 2021 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 7, 2021 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 7, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 7, 2021 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jan 7, 2021 COAR
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 7, 2020 RFCS
REFUSAL PROCESSED BY MPU
Sep 3, 2020 RFRR
APPLICATION FILING RECEIPT MAILED
Aug 7, 2020 MAFR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 4, 2020 RFCR
NON-FINAL ACTION WRITTEN
Aug 3, 2020 CNRT
ASSIGNED TO EXAMINER
Aug 3, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 3, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 30, 2020 REPR